Seoul Pharma Co. Ltd (KQ:018680) — Market Cap & Net Worth
Market Cap & Net Worth: Seoul Pharma Co. Ltd (018680)
Seoul Pharma Co. Ltd (KQ:018680) has a market capitalization of $17.98 Million (₩26.52 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25475 globally and #1846 in its home market, demonstrating a 4.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seoul Pharma Co. Ltd's stock price ₩2275.00 by its total outstanding shares 11659319 (11.66 Million). Review 018680 current and long-term liabilities to assess the company's total debt and financial obligations.
Seoul Pharma Co. Ltd Market Cap History: 2015 to 2026
Seoul Pharma Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $119.28 Million to $17.98 Million (-16.88% CAGR).
Index Memberships
Seoul Pharma Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.01% | #996 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.01% | #996 of 1384 |
Weight: Seoul Pharma Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Seoul Pharma Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seoul Pharma Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Seoul Pharma Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Seoul Pharma Co. Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $119.28 Million | $44.73 Billion | -$783.06 Million | 0.00x | N/A |
| 2016 | $72.94 Million | $45.92 Billion | $816.80 Million | 0.00x | 0.09x |
| 2017 | $86.19 Million | $46.65 Billion | $881.44 Million | 0.00x | 0.10x |
| 2018 | $45.50 Million | $44.14 Billion | -$4.35 Billion | 0.00x | N/A |
| 2019 | $53.26 Million | $53.95 Billion | -$1.87 Billion | 0.00x | N/A |
| 2020 | $86.52 Million | $52.23 Billion | -$1.34 Billion | 0.00x | N/A |
| 2021 | $62.03 Million | $40.46 Billion | -$9.69 Billion | 0.00x | N/A |
| 2022 | $39.74 Million | $50.06 Billion | $855.09 Million | 0.00x | 0.05x |
| 2023 | $30.26 Million | $52.46 Billion | $3.52 Billion | 0.00x | 0.01x |
| 2024 | $26.15 Million | $53.58 Billion | $1.70 Billion | 0.00x | 0.02x |
Competitor Companies of 018680 by Market Capitalization
Companies near Seoul Pharma Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Seoul Pharma Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Seoul Pharma Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Seoul Pharma Co. Ltd's market cap moved from $119.28 Million to $ 17.98 Million, with a yearly change of -16.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩17.98 Million | -26.14% |
| 2025 | ₩24.34 Million | -6.95% |
| 2024 | ₩26.15 Million | -13.58% |
| 2023 | ₩30.26 Million | -23.86% |
| 2022 | ₩39.74 Million | -35.92% |
| 2021 | ₩62.03 Million | -28.31% |
| 2020 | ₩86.52 Million | +62.46% |
| 2019 | ₩53.26 Million | +17.05% |
| 2018 | ₩45.50 Million | -47.21% |
| 2017 | ₩86.19 Million | +18.17% |
| 2016 | ₩72.94 Million | -38.85% |
| 2015 | ₩119.28 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Seoul Pharma Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.98 Million USD |
| MoneyControl | $17.98 Million USD |
| MarketWatch | $17.98 Million USD |
| marketcap.company | $17.98 Million USD |
| Reuters | $17.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more